On December 20, 2022 QureBio Ltd., a clinical-stage biopharmaceutical company focusing on development of bispecific antibodies and other engineered Biopharmaceuticals for the treatment of cancer, inflammation, and other serious disorders, reported that Phase Ⅰ Clinical Data of its Q-1802 program will be presented at ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium (ASCO-GI) hold at the San Francisco and online on January 19–21, 2023 (Press release, QureBio, DEC 20, 2022, View Source;data-at-2023-asco-gi-meetings-301707202.html [SID1234625460]). The abstract will be found in 2023 ASCO (Free ASCO Whitepaper) Gastrointestinal Cancers Symposium–Meeting Abstracts (#382) and a brief of the abstract information is shown as below:
Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:
Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing
Schedule Your 30 min Free Demo!
Interim results of a first-in-human phase 1 study of Q-1802, a CLDN18.2/PD-L1 bsABs in patients with relapsed or refractory solid tumors
Authors: Yakun Wang1, Jifang Gong1, Yuping Sun2, Jian Zhang3, Yanqiao Zhang4 ,Shuqin ni2, Jie Hou5, Xiaohua Chen5, Yusheng Wang6, Qin Yu7, Xiangdong Qu8, Yejie Du8, Li Wei8, Tao Yu8, Lin Shen1
Q-1802 is a humanized bispecific antibody
targets both the tumor -specific antigen CLDN18.2 and the immune checkpoint PD-L1
Q-1802 has excellent safety, tolerability
Q-1802 has excellent anti-tumor activity in CLDN18.2 positive GI patients
About Q-1802
Q-1802, a humanized bispecific antibody, is the first FDA-approved and the first enter clinical trial Claudin18.2/PD-L1 bispecific antibody，as well as the first to present clinical data at ASCO (Free ASCO Whitepaper) annual meeting. It recruits multiple immune mechanisms to kill tumor cells, offering a novel therapeutic opportunity for Claudin18.2 positive solid tumors. Q-1802 exhibits high affinity and selectivity, and patients with low or high expression of CLDN18.2 can benefit from it. The current clinical phase I data verify both superior anti-tumor activities and excellent safety profiles. The molecular design of Q-1802 is rational and effective, the production process is robust with high yield.